Bioequivalence Study of Torrent Pharmaceutical Limited's ISMN 120 mg ER Tablets Under Fasting Condition

Healthy Clinical Trial

Official title:

An Open Label, Randomized, Two Treatment, Two Sequence, Two Period, Cross-over, Single-dose Comparative Oral Bioavailability Study of Isosorbide Mononitrate 120 mg ER Tablets (Test) of Torrent Pharmaceuticals Ltd., India and Isosorbide Mononitrate 120 mg ER Tablets (Reference) of Kremers Urban, USA in Healthy, Adult, Male, Human Subjects Under Fasting Conditions

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01418534
• Other study ID #: 179/09
• Status: Completed
• Phase: Phase 1
• First received: August 11, 2011
• Last updated: August 16, 2011

Study information

• Verified date: August 2011
• Source: Torrent Pharmaceuticals Limited
• Contact: n/a
• Is FDA regulated: No
• Health authority: India: Drugs Controller General of IndiaIndia: Indian Council of Medical Research
• Study type: Interventional

Clinical Trial Summary

Objective:

to compare the single dose bioavailability of Torrent's Isosorbide Mononitrate 120 mg ER Tablets (Test) and Isosorbide Mononitrate 120 mg ER Tablets (Reference) of Kremers Urban, USA. Dosing periods were separated by a washout period of 8 days.

Study Design:

randomized, two-way crossover, single-dose, open-label study in healthy human adult subjects

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Healthy males within the age range of 18 to 55 years.

• A body mass index within 18-25 Kg/m2.

• Given written informed consent to participate in the study.

• Absence of diseases markers of HIV 1 & 2, Hepatitis B & C virus and RPR.

• Absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluation, medical history and physical examination during the screening.

• A normal 12-lead ECG.

• A normal chest X-Ray.

• Comprehension of the nature and purpose of the study and compliance with the requirements of the entire protocol.

• No history or no evidence of hypersensitivity or idiosyncratic reactions to other nitrates or nitrites.

• No history of allergic rash.

• No history of significant systemic diseases.

• No history of psychiatric disorders or addiction to any recreational drug or drug dependence.

• No donation of blood within 56 days prior to study check-in.

• No participation in any clinical study within the past 56 days.

• No receipt of any prescription drugs or OTC products, with in two weeks prior to study check-in.

• No history of dehydration from diarrhea, vomiting or any other reason within a period of 24 hours prior to study check-in.

• No family history of neurological disorders.

• Not consumed alcohol and xanthine containing food and beverages, cigarettes and tobacco products, for at-list 48 hours, prior to study check-in.

• Negative results for drugs of abuse in urine and alcohol breath analysis during check-in of each period.

• Not consumed grape fruit juice within the 48 hours prior to study check-in.

Exclusion Criteria:

• Blood pressure Systolic> 140 mm Hg and < 110 mm Hg Diastolic< 70 mm Hg > 90 mm Hg

• History of seizures

• History of alcohol consumption for more than 2 units/day.

• High caffeine or tobacco consumption

• History of difficulty with donating blood or difficulty in accessibility of veins.

• Any unusual or abnormal diet, for whatever reason e.g. fasting due to religious reasons.

• Used any pharmacological agents known to significantly induce or inhibit drug metabolizing enzymes within 14 days of the start of the study.

Study Design

N/A

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• Torrent's Isosorbide Mononitrate 120 mg ER Tablets

Locations

Country	Name	City	State
India	Trident Life sciences Limited	Hyderabad	AP
India	Trident Life Sciences Limited	Hydrabad	AP

Sponsors (1)

Lead Sponsor	Collaborator
Torrent Pharmaceuticals Limited

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	bioequivalence based on Composite of Pharmacokinetics	bioequivalence; 90% geometric confidence interval of the ratio of least-squares means of the test to reference product should be within 80.00% - 125.00% for AUC-unf, AUCo-t and Cmax.		No